January 15, 2026

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.

Conexiant

July 26, 2023

Volume of Liver Resected During Gallbladder Surgery May Not Significantly Affect Overall Survival in Patients With Gallbladder Cancer

Investigators have found that overall survival rates may not vary significantly among patients with gallbladder cancer who have had different volumes of their livers resected, as long as the cancer is...

The ASCO Post

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

July 26, 2024

Healing and Owing: U.S. Health Workers' $150 Billion Debt Dilemma

A new study exposes the alarming levels of medical and educational debt burdening U.S. health care workers, with debt disproportionately affecting women, Black workers, and those in lower-paying fields.

Conexiant

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

March 14, 2025

Incretin Drugs Linked to Gallbladder Disease Risk

Prescribers should be aware of the risk of gallbladder and biliary tract diseases when using incretin-based drugs in patients with T2D regardless of BMI status, study shows.

Conexiant

December 03, 2024

FDA Greenlights Yesintek Biosimilar

Conexiant

April 18, 2025

Gallstone Recurrence Rates Post Nonoperative Management

"Delayed cholecystectomy should be prioritized for younger patients with a history of gallstone disease if early cholecystectomy is not feasible."

Conexiant

September 24, 2025

Surgery Versus GLP-1: Long-Term Diabetes Outcomes

Metabolic surgery associated with lower mortality and retinopathy risk versus glucagon-like peptide-1 therapy in diabetes and obesity.

Conexiant